MitoRx Therapeutics raises £5.5m in a pre-Series A funding round led by Oshen Holdings to advance its obesity therapy Myo-004.
Amount Raised
£5.5 Million
Round Type
Pre-Series A
OxfordBiotechnologyHealth CareTherapeuticsInvestors
Description
MitoRx Therapeutics Ltd has successfully completed a £5.5m pre-Series A funding round led by Oshen Holdings. This funding will accelerate the development of Myo-004, a small molecule obesity therapy. Myo-004 aims to promote weight loss while preserving lean muscle mass. The investment is crucial for moving forward in clinical candidate selection and continuing their development programs.
Who to call at MitoRx Therapeutics, and when
A new round usually means MitoRx Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day MitoRx Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at MitoRx Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at MitoRx Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment MitoRx Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
MitoRx Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.